Recent Updates
Recently added Catalysts

Tacabrutideg

Phase 3

CLL | Small molecule | Oncology |BeOne Medicines Ltd.|Last Updated: Aug 26, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment250

FDA Designations

No designations recorded

Clinical trial landscape

Tacabrutideg · 4 trials · 13 indications

Phase 3 2Phase 1 2
NCT06973187A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaChronic Lymphocytic Leukemia
RECRUITING500 Analytics
NCT06846671A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsCLL
RECRUITING250 Analytics
PHASE3RECRUITING
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaUnlock trial analytics
PHASE3RECRUITING
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
CLLUnlock trial analytics

Study Endpoints

Primary Endpoints

Progression-Free Survival (PFS) per Independent Review Committee (IRC)
Up to approximately 3 years

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL).

Progression-Free Survival (PFS) by Independent Review Committee (IRC)
Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL).

Substudy 1 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse events
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 1 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse events
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 2 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse events
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 2 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse events
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 3 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse events
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 3 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse events
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years]
Substudy 4 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse events
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 4 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse events
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Phase 1: Number of Participants with Adverse Events (AEs)
From the first dose of tacabrutideg until 30 days after the last dose of the study drug or before the initiation of a new anticancer therapy, whichever occurs first (Up to 47 weeks)

Number of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) including results from laboratory assessments, electrocardiograms (ECGs), and physical examinations, and that meet protocol-defined dose-limiting toxicities (DLTs); as graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Tacabrutideg
Approximately 28 days

MTD is defined as the highest evaluated dose with an estimated toxicity rate closest to the target, while MAD is the highest dose given if MTD is not reached.

Phase 1: Recommended dose(s) for Expansion (RDFE) of tacabrutideg
Approximately 3 years

RDFE of tacabrutideg alone will be determined based upon the MTD or MAD.

Phase 2: Overall response rate (ORR)
approximately 3 years

Defined as the percentage of participants achieving a best overall response of partial response (PR) or better, assessed by the Independent Review Committee for participants with R/R CLL/SLL and R/R WM (in participants with WM, this is also referred to as major response rate) and by the investigator for other cohorts (R/R MCL, R/R MZL, R/R FL, R/R non-GCB DLBCL, R/R Richter's transformation to DLBCL), evaluated using the Lugano criteria for NHL and SLL, International Workshop of Chronic Lymphocytic Leukemia (iwCLL) criteria for CLL, and the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) criteria for WM.

Secondary Endpoints

Overall Survival (OS)
Up to approximately 3 years
PFS per Investigator (INV)
Up to approximately 3 years
Overall Response Rate (ORR) per IRC and INV
Up to approximately 3 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm A: TacabrutidegEXPERIMENTALParticipants will receive tacabrutideg orally.
Arm B: PirtobrutinibACTIVE_COMPARATORParticipants will receive pirtobrutinib orally.
Arm A: Tacabrutideg monotherapyEXPERIMENTALParticipants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met
Arm B: Investigator's ChoiceACTIVE_COMPARATORParticipants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment.
Substudy 1 Part 1a: Dose EscalationEXPERIMENTALSequential cohorts of increasing dose level combinations of tacabrutideg and sonrotoclax will be evaluated in participants with selected B-cell malignancies.
Substudy 1 Part 1b: Safety ExpansionEXPERIMENTALCohorts of select dose level combinations of tacabrutideg and sonrotoclax will be evaluated in participants with selected B-cell malignancies.
Substudy 2 Part 1a: Dose EscalationEXPERIMENTALSequential cohorts of increasing dose level combinations of tacabrutideg and zanubrutinib will be evaluated in participants with selected B-cell malignancies.
Substudy 2 Part 1b: Safety ExpansionEXPERIMENTALCohorts of select dose level combinations of tacabrutideg and zanubrutinib will be evaluated in participants with selected B-cell malignancies.
Substudy 3 Part 1a: Dose EscalationEXPERIMENTALSequential cohorts of increasing dose level combinations of tacabrutideg and mosunetuzumab will be evaluated in participants with selected B-cell malignancies.
Substudy 3 Part 1b: Safety ExpansionEXPERIMENTALCohorts of select dose level combinations of tacabrutideg and mosunetuzumab will be evaluated in participants with selected B-cell malignancies.
Substudy 4 Part 1a: Dose EscalationEXPERIMENTALSequential cohorts of increasing dose level combinations of tacabrutideg and glofitamab will be evaluated in participants with selected B-cell malignancies. Participants will receive obinutuzumab as pretreatment prior to the start of combination treatment.
Substudy 4 Part 1b: Safety ExpansionEXPERIMENTALCohorts of select dose level combinations of tacabrutideg and glofitamab will be evaluated in participants with selected B-cell malignancies.
Part 1a (Monotherapy Dose Escalation)EXPERIMENTALDose escalation in specific subtypes of non-Hodgkin lymphoma (NHL), including relapsed or refractory (R/R) marginal zone lymphoma (MZL), R/R follicular lymphoma (FL) Grades 1, 2, and 3a, R/R mantle cell lymphoma (MCL), R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), R/R diffuse large B-cell lymphoma (DLBCL), R/R Richter's transformation (RT), and R/R Waldenström macroglobulinemia (WM), to evaluate the safety and tolerability of tacabrutideg.
Part 1b (Monotherapy Safety Expansion)EXPERIMENTALParticipants with R/R MZL, MCL, CLL/SLL, and WM will be enrolled at selected doses to help determine the recommended dose(s) for expansion (RDFE(s)) for tacabrutideg.
Part 1c (Additional Monotherapy Safety Expansion)EXPERIMENTALAdditional safety data will be collected from participants with R/R MZL, WM, RT, DLBCL, or FL to confirm the RDFE(s) of tacabrutideg for those with non-CLL/SLL/MCL histologies.
Part 1d (Additional Monotherapy Safety Expansion in R/R CLL/SLL)EXPERIMENTALParticipants with R/R CLL/SLL will be enrolled at selected RDFE(s) to generate additional safety and efficacy data for tacabrutideg.
Part 1e (Japan-only Cohort)EXPERIMENTALJapanese participants with R/R MZL, FL, MCL, CLL/SLL, and WM will be enrolled at selected RDFE(s) to assess the safety and tolerability of tacabrutideg.
Part 1f (Additional Monotherapy Safety Expansion in BTKi Naive B-Cell Malignancies)EXPERIMENTALParticipants with CLL/SLL, MCL, WM, MZL, or Richter's transformation to DLBCL who have not received a prior BTKi (either covalent or noncovalent) will be enrolled at selected dose levels.
Phase 2 (Monotherapy Expansion)EXPERIMENTALCohorts of participants with R/R CLL/SLL, R/R MCL, R/R WM, R/R MZL, R/R FL, R/R RT, and R/R DLBCL will be enrolled to receive the RDFE(s) identified in Phase 1 to further evaluate the safety and efficacy of tacabrutideg.

Interventions

NameTypeDescription
TacabrutidegDRUGTacabrutideg will be administered orally
PirtobrutinibDRUGPirtobrutinib will be administered orally
BendamustineDRUGAdministered intravenously
IdelalisibDRUGAdministered orally
RituximabDRUGAdministered intravenously
VenetoclaxDRUGAdministered orally
SonrotoclaxDRUGAdministered orally
ZanubrutinibDRUGAdministered orally
MosunetuzumabDRUGAdministered subcutaneously
GlofitamabDRUGAdministered intravenously
ObinutuzumabDRUGAdministered intravenously
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites209

Inclusion Criteria: * Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 iwCLL criteria * Previously received treatment for CLL/SLL with a covalent Bruton tyrosine kinase inhibitor (cBTKi). Patients should have disease relapsed after or refractory to at least 1 line of therapy in...

Countries:United StatesArgentinaAustraliaAustriaBelgiumBrazilChinaFranceGermanyIsraelItalyJapanMexicoNetherlandsNew ZealandPolandPuerto RicoRomaniaSingaporeSouth KoreaSpainSwedenSwitzerlandUnited KingdomCanadaCzechiaTurkey (Türkiye)GeorgiaMoldova
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMAug 26, 2026NCT06973187lastUpdatePostDate: changed
MEDIUMAug 26, 2026NCT06973187lastUpdatePostDate: changed
MEDIUMAug 24, 2026NCT06846671lastUpdatePostDate: changed
MEDIUMAug 24, 2026NCT06846671lastUpdatePostDate: changed
MEDIUMAug 21, 2026NCT05006716lastUpdatePostDate: changed
MEDIUMAug 21, 2026NCT06634589lastUpdatePostDate: changed
MEDIUMAug 21, 2026NCT05006716lastUpdatePostDate: changed
MEDIUMAug 21, 2026NCT06634589lastUpdatePostDate: changed
LOWAug 20, 2026NCT05006716lastUpdatePostDate: changed
LOWAug 20, 2026NCT06634589lastUpdatePostDate: changed
LOWAug 20, 2026NCT05006716lastUpdatePostDate: changed
LOWAug 20, 2026NCT06634589lastUpdatePostDate: changed
LOWAug 20, 2026NCT05006716lastUpdatePostDate: changed
LOWAug 20, 2026NCT06634589lastUpdatePostDate: changed
LOWAug 20, 2026NCT05006716lastUpdatePostDate: changed
LOWAug 20, 2026NCT06634589lastUpdatePostDate: changed
LOWAug 7, 2026NCT06846671lastUpdatePostDate: changed
LOWAug 7, 2026NCT06846671lastUpdatePostDate: changed
LOWAug 6, 2026NCT06973187lastUpdatePostDate: changed
LOWAug 6, 2026NCT05006716lastUpdatePostDate: changed

Frequently asked questions about Tacabrutideg

What is Tacabrutideg used for?

Tacabrutideg is an investigational small molecule being developed for B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, Waldenström macroglobulinemia, and diffuse large B-cell lymphoma. It is also studied in relapsed or refractory B-cell malignancies and in patients previously exposed to BTK and BCL2 inhibitors.

Who makes Tacabrutideg?

Tacabrutideg is being developed by BeOne Medicines Ltd., a company listed under the ticker ONC. The drug is currently in clinical development for B-cell malignancies and chronic lymphocytic leukemia.

What phase is Tacabrutideg in?

Tacabrutideg is in Phase 1 clinical trials for B-cell malignancies, with two active Phase 1 studies recruiting participants. It is also being investigated in two Phase 3 trials for chronic lymphocytic leukemia and small lymphocytic lymphoma. The drug is investigational and not yet approved.

What clinical trials is Tacabrutideg in?

Tacabrutideg is being studied in several trials, including NCT05006716, a Phase 1 dose-escalation and expansion study in B-cell malignancies; NCT06634589, a Phase 1 combination study in relapsed or refractory B-cell malignancies; NCT06846671, a Phase 3 trial versus investigator's choice in CLL or SLL previously exposed to BTK and BCL2 inhibitors; and NCT06973187, a Phase 3 trial versus pirtobrutinib in relapsed or refractory CLL or SLL.

Is Tacabrutideg the same as BGB-16673?

Yes, Tacabrutideg is also known as BGB-16673. Clinical trial records refer to the drug by both names, with BGB-16673 appearing in the titles of the studies. This alternative name is used interchangeably in research contexts.

What is the enrollment and design of Tacabrutideg trials?

The Tacabrutideg clinical program includes two Phase 1 trials with a combined enrollment of 725 participants, both randomized and controlled but not double-blind. The Phase 3 trials have enrollments of 250 and 500 participants respectively. All trials are actively recruiting and none have been completed.